Page last updated: 2024-09-05

sb 203580 and Allergic Neuritis, Experimental

sb 203580 has been researched along with Allergic Neuritis, Experimental in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, H; Guo, X; Li, G; Liang, L; Ma, S; Sun, Y; Wang, M; Wang, W; Zheng, Y; Zhong, D	1

Other Studies

1 other study(ies) available for sb 203580 and Allergic Neuritis, Experimental

Article	Year
Administration of SB203580, a p38 MAPK Inhibitor, Reduced the Expression of MMP9, and Relieved Neurologic Severity in the Experimental Autoimmune Neuritis (EAN) in Rats. Neurochemical research, 2015, Volume: 40, Issue:7 Topics: Animals; Female; Imidazoles; Matrix Metalloproteinase 9; Neuritis, Autoimmune, Experimental; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred Lew; Sciatic Nerve; Transcription Factor AP-1	2015

Article

Year

Administration of SB203580, a p38 MAPK Inhibitor, Reduced the Expression of MMP9, and Relieved Neurologic Severity in the Experimental Autoimmune Neuritis (EAN) in Rats.

Neurochemical research, 2015, Volume: 40, Issue:7

Topics: Animals; Female; Imidazoles; Matrix Metalloproteinase 9; Neuritis, Autoimmune, Experimental; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred Lew; Sciatic Nerve; Transcription Factor AP-1

2015